Cardiovascular risk estimations from the risk scores, calculated for the patients with RA included in the study.
| ERS-RA (reported) | |
| Male and female patients | 6.3 (3.0–11.5) |
| Female patients | 4.7 (2.4–8.3) |
| Male patients | 10.6 (5.4–16.8) |
| ESR ≥ 40 mm/h, female and male | 7.2 (4.1–12.9) |
| ERS-RA (measured) | |
| Male and female patients | 8.3 (3.9–14.8) |
| Female patients | 6.4 (3.2–11.9) |
| Male patients | 12.8 (7.7–20.7) |
| ESR ≥ 40 mm/h, female and male | 9.8 (5.3–16.6) |
| ACC/AHA | |
| Male and female patients | 6.3 (2.4–13.2) |
| Female patients | 4.4 (1.7–9.2) |
| Male patients | 11.8 (6.4–19.8) |
| ESR ≥ 40 mm/h, female and male | 7.6 (3.2–14.9) |
| ACC/AHA × 1.5 | |
| Male and female patients | 9.4 (3.6–19.9) |
| Female patients | 6.6 (2.6–13.7) |
| Male patients | 17.7 (9.7–29.7) |
| ESR ≥ 40 mm/h, female and male | 11.4 (4.8–22.3) |
Risk is presented as median 10-year risk of cardiovascular event in % (IQR). RA: rheumatoid arthritis; ERS-RA: Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis; ESR: erythrocyte sedimentation rate; ACC/AHA: American College of Cardiology/American Heart Association; IQR: interquartile range.